Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Diseases, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines.
We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries.
ENTYVIO is a prescription medicine used in adults for the treatment of:
moderately to severely active ulcerative colitis
moderately to severely active Crohn’s disease
JOIN THE LIVE EVENT
Mary Carol Usewicz
Connect with us on Social Media
Search tags: IBD, inflammatory bowel disease, UC, CD, ulcerative colitis, crohn’s disease, Entyvio, anti-integrin